CALCIUM DIGLUTAMATE

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C5H7NO4.Ca.2H
Molecular Weight	332.321
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H+].[H+].[Ca++].N[C@@H](CCC([O-])=O)C([O-])=O.N[C@@H](CCC([O-])=O)C([O-])=O

InChI

InChIKey=UMVAYAXXQSFULN-QHTZZOMLSA-L

InChI=1S/2C5H9NO4.Ca/c2*6-3(5(9)10)1-2-4(7)8;/h2*3H,1-2,6H2,(H,7,8)(H,9,10);/q;;+2/p-2/t2*3-;/m00./s1

HIDE SMILES / InChI

Molecular Formula	Ca
Molecular Weight	40.078
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C5H7NO4
Molecular Weight	145.1134
Charge	-2
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H
Molecular Weight	1.0079
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.html
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details

Anhydrous dibasic calcium phosphate is a calcium salt of phosphoric acid. It is used as a diluent in pharmaceutical industry, in some toothpastes as a polishing agent. Calcium phosphate is generally recognized as safe by FDA. Dibasic calcium phosphate is ised as a supplement to treat conditions associated with calcium deficit, such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Hypocalcemia 75 Sources: http://www.globalrph.com/calcium_supplements.htm	Primary	Not Provided 504	Unknown Approved Use Unknown
Chronic obstructive pulmonary disease 174 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26265479	Palliative	Phase I 428	Unknown Approved Use Unknown
Cystic fibrosis 120 Sources: https://clinicaltrials.gov/ct2/show/NCT01543191	Palliative	Phase I 428	Unknown Approved Use Unknown
Unknown 2578
Hypocalcemia 75 Sources: https://www.drugs.com/mmx/calcium-phosphate-dibasic.html	Primary	Approved 8429	Unknown Approved Use Hypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred

PubMed

Title	Date	PubMed
Studies on the calcemic effect of intravenous secretin in humans.	1975 Jun	1220513
A novel ubiquitously expressed alpha-latrotoxin receptor is a member of the CIRL family of G-protein-coupled receptors.	1999 Feb 26	10026162
Ni2+ transport by the human Na+/Ca2+ exchanger expressed in Sf9 cells.	1999 May	10329968
C-reactive protein in the hemolymph of Achatina fulica: interrelationship with sex steroids and metallothionein.	2000 Apr	10840224
NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways.	2000 Jul 17	10899114
Polyoxygenated dysidea sterols that inhibit the binding of [I125] IL-8 to the human recombinant IL-8 receptor type A.	2000 May	10843593
Dual regulation of leptin secretion: intracellular energy and calcium dependence of regulated pathway.	2000 May	10780946
High-calcium diet enhances vasorelaxation in nitric oxide-deficient hypertension.	2000 Sep	10993766
Characterization of the human cysteinyl leukotriene 2 receptor.	2000 Sep 29	10851239
Ca2+-induced contraction of cat esophageal circular smooth muscle cells.	2001 Apr	11245615
Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity.	2001 Apr 27	11278295
Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds.	2001 Dec 21	11592964
Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy.	2001 Jun 8	11382382
Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors.	2001 Mar 15	11238657
Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes.	2001 Mar 2	11230109
Familial intrahepatic cholestasis 1: studies of localization and function.	2001 Oct	11584374
Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2+) channels.	2001 Oct 12	11597992
Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze.	2001 Sep 7	11553362
Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats.	2002	12421626
Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells.	2002 Dec	12456425
Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene.	2002 Feb	11796525
Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons.	2002 Nov 4	12445469
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death.	2002 Sep 6	12383957
Henri Moissan: winner of the Nobel Prize for Chemistry 1906.	2006 Oct 20	16960820
Effect of calcium phosphate and vitamin D₃ supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron.	2014 Jan 17	24438153
Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review.	2014 Jul	24705069
Dietary interventions for mineral and bone disorder in people with chronic kidney disease.	2015 Sep 16	26376110

Patents

Sample Use Guides

In Vivo Use Guide

oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid). inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:11:05 GMT 2023` Edited by `admin` on `Fri Dec 15 15:11:05 GMT 2023`
Record UNII	9FA5OTO85L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CALCIUM DIGLUTAMATE

Systematic Name

English

CALCIUM GLUTAMATE

Systematic Name

English

MONOCALCIUM DI-L-GLUTAMATE

Systematic Name

English

Calcium glutamate [WHO-DD]

Common Name

English

CALCIUM DI-L-GLUTAMATE

Systematic Name

English

INS NO.623

Code

English

INS-623

Code

English

CALCIUM DIGLUTAMATE ANHYDROUS

Common Name

English

E-623

Code

English

Classification Tree Code System Code

JECFA EVALUATION

INS-623